Aerami KOL Call: Inhaled Imatinib (AER-901) for the Treatment of Pulmonary Arterial Hypertension August 18, 2020 Continue Reading
Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium July 23, 2020 Continue Reading
Durham-based startup targeting diabetes raises $4.6M, looks for another $10.4M June 19, 2020 Continue Reading
Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline June 8, 2020 Continue Reading
Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer February 5, 2020 Continue Reading